www.roche.com
Global Alliance to Jointly Discover Novel Drugs
Roche and Evotec today have formed an alliance to jointly discover and develop compounds against a target for CNS diseases and other indications. Leveraging the expertise developed by Evotec on this target, and as part of their CNS drug discovery focus, Evotec and Roche will collaborate to identify inhibitors involved in the potential treatment of a range of diseases. Both companies believe that this target is of high priority and that partnering their respective drug discovery efforts and expertise will bring about the successful and timely discovery of new drugs.
"This agreement builds on the strategic alliance that Roche and Evotec have established over the last five years. Through the multiple dimensions of the Roche-Evotec relationship we are endeavoring to develop compounds that will make a difference in patients lives."
Dr Peter Hug, Global Head of Pharma Partnering, Roche